ARS Pharmaceuticals Analyst Ratings
ARS Pharmaceuticals Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/14/2023 | 119.62% | Wedbush | → $15 | Reiterates | Outperform → Outperform |
| 06/21/2023 | 119.62% | Wedbush | $17 → $15 | Maintains | Outperform |
| 05/18/2023 | 148.9% | Wedbush | → $17 | Reiterates | Outperform → Outperform |
| 05/12/2023 | 148.9% | Wedbush | → $17 | Reiterates | Outperform → Outperform |
| 05/10/2023 | 148.9% | Wedbush | → $17 | Reiterates | → Outperform |
| 01/31/2023 | 46.41% | Wedbush | → $10 | Initiates Coverage On | → Outperform |
| 01/04/2023 | — | William Blair | Initiates Coverage On | → Outperform | |
| 12/13/2022 | 104.98% | SVB Leerink | → $14 | Initiates Coverage On | → Outperform |
| 日期 | 上行/下行 | 分析公司 | 目標價格變化 | 評級變化 | 上一次/當前評級 |
|---|---|---|---|---|---|
| 2023年08月14日 | 119.62% | 韋德布什 | →$15 | 重申 | 跑贏→跑贏大盤 |
| 2023年6月21日 | 119.62% | 韋德布什 | $17→$15 | 維護 | 跑贏大盤 |
| 2023年05月18日 | 148.9% | 韋德布什 | →$17 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月12日 | 148.9% | 韋德布什 | →$17 | 重申 | 跑贏→跑贏大盤 |
| 2023年05月10日 | 148.9% | 韋德布什 | →$17 | 重申 | →跑贏大盤 |
| 2023年年1月31日 | 46.41% | 韋德布什 | →$10 | 開始承保 | →跑贏大盤 |
| 01/04/2023 | - | 威廉·布萊爾 | 開始承保 | →跑贏大盤 | |
| 2022年12月13日 | 104.98% | SVB Leerink | →$14 | 開始承保 | →跑贏大盤 |
What is the target price for ARS Pharmaceuticals (SPRY)?
ARS製藥公司(SPRY)的目標價是多少？
The latest price target for ARS Pharmaceuticals (NASDAQ: SPRY) was reported by Wedbush on August 14, 2023. The analyst firm set a price target for $15.00 expecting SPRY to rise to within 12 months (a possible 119.62% upside). 8 analyst firms have reported ratings in the last year.
韋德布什於2023年8月14日報道了ARS製藥(納斯達克：SPRY)的最新目標價。這家分析公司將目標價定為15美元，預計Spry將在12個月內上漲(漲幅可能為119.62)。去年有8家分析公司公佈了評級。
What is the most recent analyst rating for ARS Pharmaceuticals (SPRY)?
分析師對ARS製藥(SPRY)的最新評級是多少？
The latest analyst rating for ARS Pharmaceuticals (NASDAQ: SPRY) was provided by Wedbush, and ARS Pharmaceuticals reiterated their outperform rating.
ARS製藥(納斯達克代碼：SPRY)的最新分析師評級由韋德布什提供，ARS製藥重申其表現優於大盤的評級。
When is the next analyst rating going to be posted or updated for ARS Pharmaceuticals (SPRY)?
ARS製藥公司(SPRY)的下一次分析師評級將於何時發佈或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of ARS Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for ARS Pharmaceuticals was filed on August 14, 2023 so you should expect the next rating to be made available sometime around August 14, 2024.
分析師在進行了廣泛的研究後得出股票評級，其中包括查閱公共財務報表，與ARS製藥公司的高管和客戶交談，以及聽取收益電話會議。大多數分析師每三個月就會這樣做一次，所以你每年應該會得到每家公司每家公司的4個評級。ARS製藥的上一次評級是在2023年8月14日提交的，所以你應該預計下一次評級將在2024年8月14日左右的某個時候公佈。
Is the Analyst Rating ARS Pharmaceuticals (SPRY) correct?
分析師對ARS製藥(SPRY)的評級正確嗎？
While ratings are subjective and will change, the latest ARS Pharmaceuticals (SPRY) rating was a reiterated with a price target of $0.00 to $15.00. The current price ARS Pharmaceuticals (SPRY) is trading at is $6.83, which is within the analyst's predicted range.
雖然評級是主觀的，並將發生變化，但最新的ARS製藥(SPRY)評級被重申，目標價在0.00美元至15.00美元之間。目前ARS製藥(SPRY)的交易價格為6.83美元，在分析師的預測範圍內。